Macedonio J. Mejia

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.

J. Blake, J. Christensen, B. Brandhuber, 2018, ACS medicinal chemistry letters.

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.

G. Vigers, J. Gaudino, Jennifer N. Otten, 2020, Journal of medicinal chemistry.